[1]Rocco,SilvanaA.;Barbarini,JoseEduardo;Rittner,Roberto[Synthesis,2004,#3,p.429-435]
[2]Bridges;Zhou;Cody;Rewcastle;McMichael;Showalter;Fry;Kraker;Denny[JournalofMedicinalChemistry,1996,vol.39,#1,p.267-276]
[3]Lim,JohnK.;Negash,Kitaw;Hanrahan,StephenM.;Vanbrocklin,HenryF.[Journaloflabelledcompoundsandradiopharmaceuticals,2000,vol.43,#12,p.1183-1191]
[4]VanBrocklin,HenryF.;Lim,JohnK.;Coffing,StephanieL.;Hom,DarrenL.;Negash,Kitaw;Ono,MicheleY.;Gilmore,JenniferL.;Bryant,Ianthe;RieseII,DavidJ.[JournalofMedicinalChemistry,2005,vol.48,#23,p.7445-7456]
[5]Rewcastle;Denny;Bridges;Zhou;Cody;McMichael;Fry[JournalofMedicinalChemistry,1995,vol.38,#18,p.3482-3487]
Title: Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes.
Journal: Journal of medicinal chemistry 20051117
Title: Bridges AJ, et al. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
Title: Fry DW, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5.
Title: Bos M, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptoractivation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106.
Title: Kunkel MW, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs. 1996;13(4):295-302.
